Brief: Vericel Announces U.S. Commercial Availability Of Nexobrid® (Anacaulase-Bcdb) For The Treatment Of Severe Thermal Burns In Adults
20/09/2023 22:11
Vericel Corp VCEL.O :
* VERICEL ANNOUNCES U.S. COMMERCIAL AVAILABILITY OF
NEXOBRID®
(ANACAULASE-BCDB) FOR THE TREATMENT OF SEVERE THERMAL BURNS IN
ADULTS
Source text for Eikon: ID:nGNX2v06rV
Further company coverage: VCEL.O
Recent news on Vericel
See all newsMedTech growth concerns likely to overshadow Q3 results, Leerink says
Vericel Corp reports results for the quarter ended June 30 - Earnings Summary
Vericel beats Q2 revenue estimates, boosts annual outlook
Brief: Vericel Q2 EPS USD 0.04
Vericel beats Q1 revenue on MACI, burn care growth, lifts 2026 sales outlook